Forte Biosciences (FBRX) Change in Accured Expenses (2016 - 2026)
Forte Biosciences (FBRX) reported Change in Accured Expenses of -$198000.0 for Q1 2026, down 111.72% year-over-year from $1.7 million in Q1 2025, and down 106.07% quarter-over-quarter from $3.3 million in Q4 2025.
Forte Biosciences (FBRX) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Change in Accured Expenses data on file, last reported at -$198000.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$198000.0, down 111.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.5 million (up 172.25% YoY), and the FY2025 annual result was $8.4 million, up 7608.26% from the prior year.
- Change in Accured Expenses retreated to -$198000.0 in Q1 2026 per FBRX's latest filing, from $3.3 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.6 million in Q3 2025 and troughed at -$1.2 million in Q3 2023.
- A 5-year average of $571352.9 and a median of $135000.0 in 2022 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses tumbled 955.2% in 2024, then jumped 960.66% in 2025.
- A 5-year view of Change in Accured Expenses shows it stood at $924000.0 in 2022, then slumped by 86.47% to $125000.0 in 2023, then plunged by 955.2% to -$1.1 million in 2024, then jumped by 405.14% to $3.3 million in 2025, then plunged by 106.07% to -$198000.0 in 2026.
- Business Quant data shows FBRX's Change in Accured Expenses at -$198000.0 in Q1 2026, $3.3 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -198,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -198,000.00 |
| Mar 31, 2026 | -198,000.00 |
| Dec 31, 2025 | 3.26 Mn |
| Dec 31, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.63 Mn |
| Sep 30, 2025 | 3.63 Mn |
| Jun 30, 2025 | -181,000.00 |
| Jun 30, 2025 | -181,000.00 |
| Mar 31, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Sep 30, 2024 | -422,000.00 |
| Sep 30, 2024 | -422,000.00 |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Mar 31, 2024 | -595,000.00 |
| Mar 31, 2024 | -595,000.00 |
| Dec 31, 2023 | 125,000.00 |
| Dec 31, 2023 | 125,000.00 |